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Introduction
The term Soft Tissue Sarcomas (STS) refers to a
group of rare malignant tumours arising in the extra-
skeletal connective tissue (1). Malignant Fibrous
Histiocytoma (MFH) is the most frequent STS in
adults, as a rule primarily affecting the limbs, rarely the
abdomen. In case of abdominal involvement, the
mesenteric origin is exceptional to date only a few
cases having been described. We report two cases of
MFH of the mesentery.
Case reports
Patient n. 1
An 88-year-old female was admitted with a four-week history
of progressive abdominal distension, mild abdominal pain, abdo-
minal fullness, dyspnoea, and nausea. At physical examination, the
abdomen was distended and a 15 cm palpable mass was found,
extending from the lower epigastric to the periumbilical area, and
accompanied by ascites. At palpation, the mass was, smooth, lobu-
lated, firm, and mildly tender. 
An abdominal ultrasound scan and a total body computed
tomography were performed, showing a discrete, inhomogeneous
mass with alternated lower density fluid-like and increased density
vascularised areas (Fig.1), while both liver and lungs were clear.
Blood tests showed mild anaemia (Hb=11.4 g/dL, Ht=33.4%) and
increased CA-125 (= 980 U/ml, normal values< 30 U/ml).
At laparotomy, the mass originated from the mesentery and
involved 45 cm of the small bowel, also infiltrating an adjacent
bowel loop and the greater omentum. A double bowel resection
with radical excision of the tumour was performed. No liver or
other distant metastases were found. The neoplasm was encased in
a pseudocapsule, measured 12 x 9 x 7 cm, and weighed 4 kg. On the
cut section the mass was fleshy, white-grey, and had a soft consi-
stency. Microscopically, there was a complex structure, with fasci-
cles of spindle cells, sometimes showing a storiform growth pat-
tern, separated by epithelioid areas. Myxoid areas composed by
stromal cells showing different degrees of differentiation were also
present (Fig. 2). The cells had fusiform nuclei, sometimes with
rounded edges and mainly eosinophilic cytoplasm. In other areas
the cells had a vacuolated appearance, or showed monstrous and
gigantic nuclei. Mitotic index was high, with 15 mitoses/10 HPF.
The small bowel showed multiple infiltrations. A diagnosis of pleo-
morphic type MFH was made, which, according to the
International Union Against Cancer, was classified stage IV A,
poorly differentiated (G3) (2). 
Post-operative course was uneventful, and the patient was
discharged home 10 days after surgery. However, four months
later she presented abdominal recurrence with liver metastases and
died after two months.
Patient n. 2 
A 63-year-old female was admitted with a four-month history
of progressive abdominal distension, weight increase (6 kg), and
dyspnoea. At physical examination, there was a distended, hypo-
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mobile abdomen, while at palpation there was a large, painless,
lobulated, firm mass, extending from the right flank to the right
iliac fossa. 
Computed tomography showed a 13x17x 19 cm lesion. 
At surgery, the neoplasm consisted of three masses originating
from the mesentery, each weighing respectively 0.9, 1.5, and 6.2 kg,
which were all removed. Histology showed some areas with fasci-
cles of spindle cells variously oriented, while other areas had sto-
riform growth features, with plump spindle cells mixed with giant
pleomorphic cells, some of which multinucleated and containing
intensely eosinophilic droplets (Fig.3). A diagnosis of MFH, sto-
riform-pleomorphic type was made also in this patient. 
Post-operative course was normal, and the patient was dischar-
ged home 8 days after surgery. After 12 months, the patient is well
and has no signs of recurrent disease.
Discussion
STS are rare, representing only 1% of all human malignant neoplasms. Among all STS, MFH are the
most frequent, with highest incidence in the sixth and
seventh decades of life (3). MFH was first identified in
1963 (4), and is characterised by pleomorphic, sto-
riform, or stellate elements, all deriving from mesen-
chymal cells, which explains possible primary involve-
ment of any tissue (5). Previously to its identification,
cases of MFH were either classified as pleomorphic
liposarcoma or as rhabdomyosarcoma. The male to
female ratio is 2:1. Five main morphologic types of
MFH have been identified, which, in decreasing order
of frequency, are: 1. storiform-pleomorphic; 2.
myxoid; 3. giant-cell; 4. angiomatoid; 5. inflammatory.
Of note, is that the inflammatory type most commonly
affects the retroperitoneum and exceptionally the
limbs. Aetiology of MFH is unknown most STS arising
de novo, and only few affecting areas of previous radia-
tion exposure (3, 6, 7), fracture (8), or bone infarct (9-
11). Up to 13% of these patients develop synchronous
tumours, although this figure is probably biased by the
advanced age of this population and, therefore, it is of
no statistical significance (9). Most frequently the limbs
are involved (68% of cases), followed by the abdomen
and retroperitoneum (16%) (3), (5).
There are not known risk factors for the develop-
ment of abdominal or mesenteric MFH. Signs and
symptoms of MFH are non-specific and mainly related
to site, size, and to its speed of growth, which, similarly
to other tumours, may increase during pregnancy (12).
Paraneoplastic syndromes in MFH have only rarely
been reported (3, 13-15). When limbs are interested,
the tumours are usually discovered at an early stage,
due to the clinical findings and to the involvement of
muscles and tendons. Abdominal MFH, on the con-
trary, grow slowly and remain clinically silent for a long
time, with non-specific signs and symptoms, mainly
consisting of mere sense of abdominal weight and ten-
sion, which consorts with the huge dimensions of
these abdominal lesions when they are eventually
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Fig. 1 - Abdominal computed tomography showing a discrete, inhomoge-
neous mass with alternated lower density fluid-like and increased density
vascularised areas.
Fig. 2 - Myxoid areas composed by stromal cells showing different
degrees of differentiation (H&E x 100). 
Fig. 3 - Giant pleomorphic cells some of which multinucleated and contai-
ning intensely eosinophilic droplets (H&E x250). 
removed and implies a later diagnosis and worse pro-
gnosis (16, 17). Furthermore, the absolute lack of spe-
cific symptoms makes pre operative definitive diagno-
sis practically impossible, while blood results and
instrumental work-up is of no use to differentiate
between MFH and other sarcomas. Preoperative
work-up necessarily implies the assessment of meta-
stases in order to optimise surgical treatment.
Metastases to lymph nodes are difficult to ascertain
but seem relatively rare (4-17%)(18,19), while pulmo-
nary (90%), bone (8%), liver (1%), and bone seconda-
ries (21-57%) occur more frequently and are related to
size, grading, site, and maybe type of primary MFH (3,
17, 20-22). 
Macroscopic features vary in relation to site of
development, abdominal lesions appearing as huge,
lobulated lesions, in contrast with limb lesions which,
as a rule, are smaller, being discovered at an earlier
stage, and have, sometimes, a fusiform appearance
(17). Furthermore, while abdominal MFH appear
macroscopically well delimited and are, sometimes,
encased in a pseudocapsule, MFH affecting limbs (in
2/3 of patients located within the muscles) often
expand microscopically along the fascial planes or
along the muscular fibres, which explains the high inci-
dence of local recurrences (up to 80% of cases). On the
cut section, the neoplasm may show different features
in relation to the main component, varying from a yel-
lowish appearance in the inflammatory type (due to
xanthomatous cells) to a brownish colour in the hae-
morrhagic forms, in which bleeding can also be so
massive to turn the tumour into a fluctuating lesion,
such as in cystic haematoma (3). 
Prognosis mainly relies upon staging of the disease,
which, in turn, depends from histological grade, num-
ber of mytoses, bone, vessel, or nerve infiltration, and
metastases. Other important variables are size of the
tumour, and  possible site and type (17,19). Five-year
survival rate is 82% for MFH smaller than 5 cm, 68%
for lesions between 5 and 10 cm, and 51% for tumours
bigger than 10 cm. Histological grade is also important
for prognosis: 5-year survival rates decreasing from 80
to 60% in relation to good or moderate differentiation.
If tumour size and histological grade are conjointly
taken into account, at one extreme there is a 5-year sur-
vival rate of 93% for lesions smaller than 5 cm and with
low level of malignity, and at the other of 41% for those
tumours bigger than 10 cm and with high level of mali-
gnity (17). The weight on prognosis of MFH histologi-
cal type is debatables. Some authors considering the
histological variant irrelevant (23,26), others attributing
a different prognosis to each type, in relation to lower
tendency to metastasise of some forms, such as the
inflammatory type (3).
Treatment of MFH mainly consists of surgical
removal, and in case of abdominal lesions the treat-
ment of choice is en bloc excision. If radical surgery is
not possible, metallic clips should then be inserted
within the operative field to better target later radiothe-
rapy.  In case of MFH of the limbs, even if the lesion is
macroscopically circumscribed, at least 2 cm of appa-
rently clear tissue should be removed and, if needed,
amputation performed, in order to achieve radical
resection of the tumour, should microscopic infiltra-
tion along muscles and tendons occur. As a matter of
fact, later recurrences would be difficult to treat and of
ominous significance. 
In presence of distant metastases, while there is no
indication to treat multiple secondaries, surgical remo-
val of single pulmonary metastasis has sometimes pro-
duced good results. In case of MFH of the limbs, surgi-
cal treatment of metastases to regional lymph nodes
has been beneficial, and routine removal of regional
lymph nodes has therefore been recommended (19). 
Both chemotherapy and radiotherapy do not have
precise indications or standardised modalities of admi-
nistration. Some researches have shown MFH to be
radio-  and/or chemo-resistant (17,27-32), while others
have proven beneficial results (33-41). Such conflicting
results are probably related to the rarity of this condi-
tion, which makes it difficult to perform controlled cli-
nical trials and to compare homogenous subsets of
patients. At present, uncertainty of the results and
advanced age of these patients do not warrant their
employment, which is probably only justified in cases
selected for age and clinical stage.
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